PMC6180816_01
Case 1. A 63-year-old male post surgery and chemotherapy for colonic tumour. Post-therapy coronal fused PET/CT (a) and coronal PET (b) show mediastinal (arrow, a,b) and symmetric bilateral hilar hypermetabolic adenopathy (arrowhead, a,b). The biopsy result was consistent with sarcoid-like reaction. PET, positron emission tomography.
bjrcr.20150060.g001.jpg
PMC6180816_01_bjrcr.20150060.g001.jpg
f1
Findings: Post-therapy positron emission tomography (PET)/CT scan showed bilateral symmetric hilar and mediastinal enlarged lymph nodes with increased 18-fludeoxyglucose (FDG) activity (Figure 1).
PMC6180816_02
A 45-year-old female post therapy for breast cancer. Axial positron emission tomography image (a) and coronal maximum intensity projection image (b) show interval development of symmetric hilar adenopathy with intermediateJ 18-fludeoxyglucose activity (arrows).
bjrcr.20150060.g002.jpg
PMC6180816_02_bjrcr.20150060.g002.jpg
f2
Findings: PET/CT scan after completion of radiation therapy revealed hypermetabolic symmetric hilar lymph nodes (Figure 2).
A 45-year-old female post therapy for breast cancer. Follow-up PET/CT, axial PET (a) and coronal maximum intensity projection (b) images show complete improvement of symmetric hilar lymph nodes. PET, positron emission tomography.
bjrcr.20150060.g003.jpg
PMC6180816_02_bjrcr.20150060.g003.jpg
f3
Follow-up PET/CT scan revealed interval resolution of hypermetabolic lymph nodes (Figure 3).
PMC6180816_03
A 57-year-old male with non-Hodgkin's lymphoma. Axial fused PET/CT (a), axial PET (b) and coronal maximum intensity projection (c) revealed a left iliac wing hypermetabolic mass (arrow) and left pelvic hypermetabolic adenopathy (arrowheads, a,b). PET, positron emission tomography.
bjrcr.20150060.g004.jpg
PMC6180816_03_bjrcr.20150060.g004.jpg
f4
Findings: Initial PET/CT showed a lytic hypermetabolic mass in the left iliac wing with left pelvic hypermetabolic adenopathy (Figure 4).
A 57-year-old male with non-Hodgkin's lymphoma. First PET/CT following therapy: Coronal reformatted PET (a) and sagittal maximum intensity projection (b) show complete "metabolic" response to therapy. PET, positron emission tomography.
bjrcr.20150060.g005.jpg
PMC6180816_03_bjrcr.20150060.g005.jpg
f5
The first post-treatment PET/CT scan performed 8 months after completion of therapy showed a complete "metabolic" response (Figure 5).
A 57-year-old male with non-Hodgkin's lymphoma. Second follow-up PET/CT: Axial fused PET/CT (a) and coronal maximum intensity projection (b) images of the chest revealed new hypermetabolic mediastinal (arrowhead) and hilar adenopathy (arrows). Biopsy was consistent with sarcoid-like reaction. PET, positron emission tomography.
bjrcr.20150060.g006.jpg
PMC6180816_03_bjrcr.20150060.g006.jpg
f6
The second follow-up PET/CT scan 2 years after completion of therapy demonstrated new mediastinal/hilar hypermetabolic adenopathy (Figure 6).
A 57-year-old male with non-Hodgkin's lymphoma. The third follow-up PET/CT: Coronal maximum intensity projection (a) and axial fused PET/CT (b) show reduction in avidity of uptake of the mediastinal lymph nodes with interval development of mildly hypermetabolic abdominal lymph nodes (arrows). PET, positron emission tomography.
bjrcr.20150060.g007.jpg
PMC6180816_03_bjrcr.20150060.g007.jpg
f7
The third follow-up PET/CT scan after 2 years showed new abdominal hypermetabolic adenopathy (Figure 7) with SUV max of 8.7.
A 57-year-old male with non-Hodgkin's lymphoma. Last follow-up PET/CT: Coronal maximum intensity projection (a), axial fused PET/CT (b) showing resolution of uptake in precaval and mediastinal lymph nodes. PET, positron emission tomography.
bjrcr.20150060.g008.jpg
PMC6180816_03_bjrcr.20150060.g008.jpg
f8
The last follow-up PET/CT performed 2 years after the third follow-up PET/CT scan showed almost complete improvement of these findings (Figure 8).